These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 21843305)

  • 41. Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice.
    Schreiber SA; Russmann A
    Curr Med Res Opin; 2007 Dec; 23(12):3131-6. PubMed ID: 17988433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
    Warren E; Weatherley-Jones E; Chilcott J; Beverley C
    Health Technol Assess; 2004 Nov; 8(45):iii, 1-57. PubMed ID: 15525480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes.
    Rhoads GG; Dain MP; Zhang Q; Kennedy L
    Diabetes Obes Metab; 2011 Aug; 13(8):711-7. PubMed ID: 21410859
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes.
    Home PD; Meneghini L; Wendisch U; Ratner RE; Johansen T; Christensen TE; Jendle J; Roberts AP; Birkeland KI
    Diabet Med; 2012 Jun; 29(6):716-20. PubMed ID: 22150786
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.
    Yki-Järvinen H; Kauppinen-Mäkelin R; Tiikkainen M; Vähätalo M; Virtamo H; Nikkilä K; Tulokas T; Hulme S; Hardy K; McNulty S; Hänninen J; Levänen H; Lahdenperä S; Lehtonen R; Ryysy L
    Diabetologia; 2006 Mar; 49(3):442-51. PubMed ID: 16456680
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
    Aschner P; Chan J; Owens DR; Picard S; Wang E; Dain MP; Pilorget V; Echtay A; Fonseca V;
    Lancet; 2012 Jun; 379(9833):2262-9. PubMed ID: 22683131
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
    Garber AJ; King AB; Del Prato S; Sreenan S; Balci MK; Muñoz-Torres M; Rosenstock J; Endahl LA; Francisco AM; Hollander P;
    Lancet; 2012 Apr; 379(9825):1498-507. PubMed ID: 22521072
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study.
    Schiel R; Müller UA
    Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):58-64. PubMed ID: 17973208
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
    Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C
    Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2).
    Kanazawa Y; Igarashi Y; Komiya K; Sakurai Y; Shimizu T; Fujitani Y; Tanaka Y; Watada H; Kawamori R; Hirose T
    Endocr J; 2007 Dec; 54(6):975-83. PubMed ID: 18000343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study.
    Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
    Cardiovasc Diabetol; 2009 Jan; 8():3. PubMed ID: 19152692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus.
    McKeage K; Goa KL
    Drugs; 2001; 61(11):1599-624. PubMed ID: 11577797
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
    Rosenstock J; Fonseca V; McGill JB; Riddle M; Hallé JP; Hramiak I; Johnston P; Davis M
    Diabetologia; 2009 Sep; 52(9):1778-88. PubMed ID: 19526210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes.
    Wiesli P; Krayenbühl P; Uthoff H; Seifert B; Schmid C
    Diabetologia; 2009 Sep; 52(9):1816-9. PubMed ID: 19565212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treat-to-target trials: uses, interpretation and review of concepts.
    Garber AJ
    Diabetes Obes Metab; 2014 Mar; 16(3):193-205. PubMed ID: 23668598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The relationship between self-monitored blood glucose values and glycated haemoglobin in insulin-treated patients with Type 2 diabetes.
    Sarwat S; Ilag LL; Carey MA; Shrom DS; Heine RJ
    Diabet Med; 2010 May; 27(5):589-92. PubMed ID: 20536957
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
    Raskin P; Allen E; Hollander P; Lewin A; Gabbay RA; Hu P; Bode B; Garber A;
    Diabetes Care; 2005 Feb; 28(2):260-5. PubMed ID: 15677776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.